Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX® (fulvestrant) to ARIMIDEX® (anastrozole)

Business Wire December 8, 2016

TAGRISSO® (osimertinib) Demonstrates Superiority over Chemotherapy in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Business Wire December 6, 2016

Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukemia

Business Wire December 5, 2016

Innovative Clinical Trial Implementation and Manufacturing Capacity Production Fueling Biotech Sector Growth

PR Newswire November 28, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  November 23, 2016

Research Reports on Drug Makers Equities -- Bristol-Myers Squibb, AstraZeneca, TherapeuticsMD, and Tonix Pharma

PR Newswire November 18, 2016

AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function in Pediatric Asthma Patients

Business Wire November 11, 2016

New Data Shows Frequent ICU Admissions from Severe RSV Disease among Preterm Infants in the First Three Months of Life

Business Wire October 28, 2016

Myriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib

GlobeNewswire October 26, 2016

LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

Business Wire October 26, 2016

6 Big Pharma Companies Left To Report September Quarterly Figures

Benzinga.com  October 25, 2016

Allergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans

PR Newswire October 24, 2016

Research Reports on Drug Makers Equities -- Bristol-Myers Squibb, AstraZeneca, TherapeuticsMD, and Impax Laboratories

PR Newswire October 12, 2016

Fulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer

Business Wire October 8, 2016

New Study Shows Increases in RSV Hospitalization among High-Risk Preterm Infants

Business Wire October 5, 2016

Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor

GlobeNewswire October 5, 2016

AstraZeneca's Brilinta Didn't Meet Primary Endpoint

Benzinga.com  October 4, 2016

US FDA Approves TAGRISSO® (osimertinib) Blood-Based T790M Companion Diagnostic Test

Business Wire September 29, 2016

Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes

Business Wire September 16, 2016

The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Benzinga.com  September 14, 2016